Oligonucleotide Therapy Market
完整報告名稱與涵蓋範圍
Oligonucleotide Therapy Market Size, Share & Trends Analysis Report By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User (Hospitals, Research Institutes, Others), By Region, And By Segment Forecasts, 2024-2031.
報告摘要
The Oligonucleotide Therapy Market on a global scale was estimated at USD 5.21 billion in 2023 and is forecasted to attain USD 19.92 billion by 2031, with a projected CAGR of 18.6% between 2024 and 2031.
Oligonucleotide Therapy covers some of the most promising therapeutic mechanisms for a range of hard-to-treat diseases, in particular those caused by genetic mutations. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Market momentum is supported by growing need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oligonucleotide Therapy Market Snapshot
Chapter 4. Global Oligonucleotide Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Antisense
5.2.2. Ribozymes
5.2.3. Aptamers
5.2.4. miRNA
5.2.5. CpG/Immunostimulatory
5.2.6. RNAi
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Infectious Diseases
6.2.2. Oncology
6.2.3. Neurodegenerative Disorders
6.2.4. Cardiovascular Diseases
6.2.5. Kidney Diseases
6.2.6. Others
Chapter 7. Market Segmentation 3: by End Users Estimates & Trend Analysis
7.1. by End Users & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End Users:
7.2.1. Hospitals
7.2.2. Research Institutes
7.2.3. Others
Chapter 8. Oligonucleotide Therapy Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.1.2. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.1.3. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.1.4. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.2. Europe
8.2.1. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.2.2. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.2.3. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.2.4. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.3.2. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.3.3. Asia-Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.3.4. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.4. Latin America
8.4.1. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.4.2. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.4.3. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.4.4. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.5.2. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.5.3. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.5.4. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. BPCI Biotech Holding
9.2.2. SomaGenics Inc.
9.2.3. Hepion Pharmaceuticals
9.2.4. Alnylam Pharmaceuticals
9.2.5. Regulus Therapeutics Inc.
9.2.6. Ionis Pharmaceuticals
9.2.7. Gilead Sciences Inc.
9.2.8. Santaris
9.2.9. InteRNA Technologies B.V.
9.2.10. Mirage
9.2.11. Biogen
9.2.12. Merck KGaA
9.2.13. Pfizer Inc.
9.2.14. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們